EUVIMEDEUVIMED entdecken
Crossref

FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer

Deblina Ghosh, Aslamuzzaman Kazi, Hitesh Kumar Kantilal Vasiyani, Vignesh Vudatha, Nicolas Lecomte, Christine Iacobuzio-Donahue, Jose Trevino, Said M Sebti

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Deblina Ghosh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Massey Comprehensive Cancer Center, Virginia Commonwe…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras), Pyridines. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)PyridinesExtracellular Signal-Regulated MAP KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorApoptosisCell ProliferationAlkyl and Aryl TransferasesFarnesyltranstransferaseFemaleDrug SynergismHeterocyclic Compounds, 2-RingNaphthalenesQuinolones

Stichwörter der Autor:innen

FGTI-2734FarnesyltransferaseGeranylgeranyltransferase-1KRAS G12DMRTX1133Pancreatic cancerResistance

Substanzen

KRAS protein, humanProto-Oncogene Proteins p21(ras)PyridinestipifarnibAlkyl and Aryl TransferasesFarnesyltranstransferaseExtracellular Signal-Regulated MAP Kinasesgeranylgeranyltransferase type-IKRASG12D inhibitor MRTX1133Heterocyclic Compounds, 2-Ring

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA.
  • Department of Surgery, Virginia Commonwealth University, Richmond, VA, USA; Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA.
  • David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA. Electronic address: Said.Sebti@vcuhealth.org.

Förderung

  • National Institutes of Health

Zitieren

APA

Ghosh, D., Kazi, A., Vasiyani, H. K. K., Vudatha, V., Lecomte, N., Iacobuzio-Donahue, C., Trevino, J., & Sebti, S. M. (2026). FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116255

Vancouver

Ghosh D, Kazi A, Vasiyani HKK, Vudatha V, Lecomte N, Iacobuzio-Donahue C, et al. FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116255

BibTeX
@article{Ghosh2026,
  author = {Ghosh, Deblina and Kazi, Aslamuzzaman and Vasiyani, Hitesh Kumar Kantilal and Vudatha, Vignesh and Lecomte, Nicolas and Iacobuzio-Donahue, Christine and Trevino, Jose and Sebti, Said M},
  title = {FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116255}
}
Kostenlos starten →